References
- 1. Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in haemophilia patients with high-titer inhibitors. Vasc Health Risk Manag. 2007 Aug; 3(4):527-31.
- 2. Serban M, Poenaru D, Cernat L, Savescu D, Patrascu J, Schramm W, et al. Global clotting assays - monitoring the effect of by-passing agents in haemophilia patients with inhibitors. Rev Romana Med Lab. 2017 April; 25:135-43. DOI: 10.1515/rrlm-2017-001110.1515/rrlm-2017-0011
- 3. Meek LS, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology. 2016 Dec 2; 2016(1):657-62. DOI: 10.1182/asheducation-2016.1.65710.1182/asheducation-2016.1.657614246927913543
- 4. Holmstro M, Tran HTT, Holme PA. Combined treatment with APCC (FEIBA) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience. Haemophilia. 2012 Jul; 18(4):544-9. DOI: 10.1111/j.1365-2516.2012.02748.x10.1111/j.1365-2516.2012.02748.x22348384
- 5. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in haemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study Global clotting assays. Blood. 2007 Jan; 109 (2):546-51. DOI: 10.1182/blood-2006-04-01798810.1182/blood-2006-04-01798816990605
- 6. Gringeri A, Santagostino E, Mannucci PM. Failure of Recombinant Activated Factor VII during Surgery in a Hemophiliac with High-Titer Factor VIII Antibody. Haemostasis. 1991; 21(1):1-4. DOI: 10.1159/00021619410.1159/0002161941907588
- 7. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006 Nov; 12(6):598-604. DOI: 10.1111/j.1365-2516.2006.01319.x10.1111/j.1365-2516.2006.01319.x17083509
- 8. Younga G, Ebbesenb LS, Viuffb D, Di Paolac J, Konkled BA, Negriere C, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis. 2008 Jun; 19(4):276-82. DOI: 10.1097/MBC.0b013e3283001cdc10.1097/MBC.0b013e3283001cdc18469548
- 9. Ay Y, Balkan C, Karapinar DY, Akin M, Bilenoglu B, Kavakli K. Feasibility of Using Thrombin Generation Assay (TGA) for Monitoring Bypassing Agent Therapy in Patients with Hemophilia Having Inhibitors. Clin Appl Thromb-Hem. 2013 Jul-Aug; 19(4):389-94. DOI: 10.1177/107602961243861110.1177/107602961243861122395575
- 10. Furukawa S, Nogami K, Ogiwara K, Yada K, Minami H, Shima M. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015 Jul; 13(7):1279-84. DOI: 10.1111/jth.1298710.1111/jth.1298725903848
- 11. Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, et al. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost. 2009 Dec; 103(2):351-9. DOI: 10.1160/TH09-04-021210.1160/TH09-04-021220024491
- 12. Tran HTT, Sørensen B, Bjørnsen S, Pripp AH, Tjønnfjord GE, Holme PA. Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay. Haemophilia. 2014 Dec; 21(2):1-9. DOI: 10.1111/hae.1257010.1111/hae.1257025521720
- 13. Dargaud Y, Lambert T, Trossaert T. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia. 2008 Jul; 14(Suppl. 4):20-7. DOI: 10.1111/j.1365-2516.2008.01735.x10.1111/j.1365-2516.2008.01735.x18494689
- 14. Viuff D, Andersen S, Sørensen BB, Lethagen S. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven®) therapy in haemophilia A patients. Thromb Res. 2010 Aug; 126(2):144-9. DOI: 10.1016/j.thromres.2010.05.00810.1016/j.thromres.2010.05.00820542542
- 15. Bolliger D, Seeberger MD, Tanaka KA. Principles and Practice of Thromboelastography in Clinical Coagulation Management and Transfusion Practice. Transfus Med Rev. 2012 Jan; 26(1):1-13. DOI: 10.1016/j. tmrv.2011.07.00510.1016/j.tmrv.2011.07.005
- 16. Chitlur M, Rivard GE, Lillicrap D, Mann K, Shima M, Young G, et al. Recommendations for performing thromboelastography/ thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014 Jan; 12(1):103-6. DOI: 10.1111/jth.1245810.1111/jth.1245824261669
- 17. Sørensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia. 2005 Nov; 11(Suppl. 1):1-6. DOI: 10.1111/j.1365-2516.2005.01156.x10.1111/j.1365-2516.2005.01156.x16219042
- 18. Pivalizza EG, Escobar MA. Thrombelastography-Guided Factor VIIa Therapy in a Surgical Patient with Severe Hemophilia and Factor VIII Inhibitor. Anesth Analg. 2008 Aug; 107(2):398-401. DOI: 10.1213/ane.0b013e31817b786410.1213/ane.0b013e31817b786418633014
- 19. Da Luz LT, Nascimento B, Rizoli S. Thrombelastography (TEG): practical considerations on its clinical use in trauma resuscitation. Scand J of Trauma Resusc and Emerg Med. 2013 Apr 16; 21:29. DOI: 10.1186/1757-7241-21-2910.1186/1757-7241-21-29363750523587157
- 20. Reikvama H, Steienb E, Haugeb B, Lisethc K, Hagencet KG, Størkson R, et al. Thrombelastography. Transfus Apher Sci. 2009 Apr; 40(2):119-23. DOI: 10.1016/j.transci.2009.01.01910.1016/j.transci.2009.01.01919249246
- 21. Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol. 2016 Jun; 174(4):1-12. DOI: 10.1111/bjh.1414810.1111/bjh.1414827264484
- 22. Keyand NS, Nelsestuen GL. Views on Methods for Monitoring Recombinant Factor VIIa in Inhibitor Patients. Seminars in Hematology. 2004 Jan; 41(1, Suppl 1):51-4. DOI: 10.1053/j.seminhematol.2003.11.01110.1053/j.seminhematol.2003.11.01114872422
- 23. Zhou ZY, Hay JH. Efficacy of Bypassing Agents in Patients with Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis. Clin Ther. 2012 Feb; 34(2):434-45. DOI: 10.1016/j.clinthera.2012.01.00110.1016/j.clinthera.2012.01.00122285208
- 24. Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, deCharro F, et al. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia. 2009 Mar; 15(2):420-36. DOI: 10.1111/j.1365-2516.2008.01956.x10.1111/j.1365-2516.2008.01956.x19335751
- 25. Giangrande PLF, Wilde JT, Madan B, Ludlam CA, Tuddenham EGD. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven®] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009 Mar; 15(2):501-8. DOI: 10.1111/j.1365-2516.2008.01952.x10.1111/j.1365-2516.2008.01952.x19187194